Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer

Amgen Inc AMGN announced data from a Phase 1b/2 study evaluating the combination of Lumakras (sotorasib) with Vectibix (panitumumab) in patients with KRAS G12C-mutated advanced colorectal cancer.
Related Link: Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer.
The data showed that the combination therapy led to improved response rates.
The results were detailed at the European Society for Medical Oncology (ESMO21) congress.
Findings from the study showed that among 26 patients in the efficacy analysis set, the objective response rate (ORR) was 27%, while the disease control rate (DCR) was 81%.
In the expansion cohort of sotorasib-naïve patients with refractory CRC (n=18), 33% experienced a response (confirmed and unconfirmed).
"We are excited by these CodeBreaK 101 data, which show encouraging response rates that were much higher than the 9.7% response rate observed with Lumakras monotherapy," remarked David Reese, executive vice president of R&D.
Amgen says it has initiated a new Phase 3 trial with Lumakras plus Vectibix in the third-line setting of colorectal cancer.
Price Action: AMGN stock closed 0.97% higher at $218.13 on Wednesday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

Momentum53.67

Growth51.31

Quality52.78

Value21.38

Short

Medium

Long